This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richards, J. A. Articles by Brueggemeier, R. W. Search for Related Content PubMed PubMed Citation Articles by Richards, J. A. Articles by Brueggemeier, R. W.

Prostaglandin E₂ Regulates Aromatase Activity and Expression in Human Adipose Stromal Cells via Two Distinct Receptor Subtypes

Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio 43210

Address all correspondence and requests for reprints to: Robert W. Brueggemeier, Ph.D., 250 Parks Hall, 500 West 12th Avenue, The Ohio State University, Columbus, Ohio 43210. E-mail: Brueggemeier.1{at}osu.edu.

The aromatase enzyme complex, located primarily in the stromal cells of breast tumors, catalyzes estrogen biosynthesis and is fundamental to hormone-dependent growth of breast cancer. Although an important pharmacological target, the mechanisms by which aromatase is regulated are poorly understood. Thus, regulation of aromatase activity and expression in human breast stromal cells by prostaglandin E₂ (PGE₂) was investigated. PGE₂ exerts its actions via four transmembrane receptors, EP₁, EP₂, EP₃, and EP₄, which coordinate different signal transduction pathways. Using selective receptor agonists and antagonists, the involvement of the EP₁, EP₂, and EP₃ subtypes was assessed. Enzyme activity levels in cultures of disease-free stromal cells were determined using a tritiated water-release assay. PGE₂ and agonists of EP₁ and EP₂ significantly increased aromatase activity levels, which were decreased by the corresponding antagonists. An agonist of EP₃, an inhibitory pathway, antagonized activity levels induced by PGE₂. These results were generally reflective of changes in aromatase protein expression, determined by Western blotting analysis and the pattern of mRNA expression determined by a competitive RT-PCR method. Collectively, the results demonstrate that regulation of aromatase by PGE₂ is complex and may influence the development and progression of hormone-dependent breast cancer.

This work was supported by National Cancer Institute (NCI) Grant R01-CA73698 (to R.W.B.), NIH Grant T32-GM08512 (to J.A.R.), and NCI Grant P30-CA16058.

Abbreviations: 7-APTA, 7-(4'-Amino) phenylthio-1,4-androstaediene-3,17-dione; PGE₂, prostaglandin E₂; PKA, protein kinase A; PKC, protein kinase C; TPA, tetradecanoyl phorbol acetate.

This article has been cited by other articles:

				D. W. Visscher, V. S. Pankratz, M. Santisteban, C. Reynolds, A. Ristimaki, R. A. Vierkant, W. L. Lingle, M. H. Frost, and L. C. Hartmann Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer J Natl Cancer Inst, March 19, 2008; 100(6): 421 - 427. [Abstract] [Full Text] [PDF]

				H. K. Choi, S. H. Roh, H. G. Kim, E. H. Han, H. G. Jeong, and K. W. Kang Enhanced expression of aromatase in p53-inactivated mammary epithelial cells Endocr. Relat. Cancer, March 1, 2008; 15(1): 139 - 147. [Abstract] [Full Text] [PDF]

				K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444. [Abstract] [Full Text] [PDF]

				D. Chen, S. Reierstad, Z. Lin, M. Lu, C. Brooks, N. Li, J. Innes, and S. E. Bulun Prostaglandin E2 Induces Breast Cancer Related Aromatase Promoters via Activation of p38 and c-Jun NH2-Terminal Kinase in Adipose Fibroblasts Cancer Res., September 15, 2007; 67(18): 8914 - 8922. [Abstract] [Full Text] [PDF]

				A. M. Fulton, X. Ma, and N. Kundu Targeting Prostaglandin E EP Receptors to Inhibit Metastasis. Cancer Res., October 15, 2006; 66(20): 9794 - 9797. [Abstract] [Full Text] [PDF]

				G. K. Yiu and A. Toker NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2 J. Biol. Chem., May 5, 2006; 281(18): 12210 - 12217. [Abstract] [Full Text] [PDF]

				X. Ma, N. Kundu, S. Rifat, T. Walser, and A. M. Fulton Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis. Cancer Res., March 15, 2006; 66(6): 2923 - 2927. [Abstract] [Full Text] [PDF]

				M. Watanabe, M. Noda, and S. Nakajin Effect of epidermal growth factor and prostaglandin on the expression of aromatase (CYP19) in human adrenocortical carcinoma cell line NCI-H295R cells J. Endocrinol., January 1, 2006; 188(1): 59 - 68. [Abstract] [Full Text] [PDF]

				R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz Aromatase Inhibitors in the Treatment of Breast Cancer Endocr. Rev., May 1, 2005; 26(3): 331 - 345. [Abstract] [Full Text] [PDF]

				E. R. Simpson, M. Misso, K. N. Hewitt, R. A. Hill, W. C. Boon, M. E. Jones, A. Kovacic, J. Zhou, and C. D. Clyne Estrogen--the Good, the Bad, and the Unexpected Endocr. Rev., May 1, 2005; 26(3): 322 - 330. [Full Text] [PDF]

				E. S. Diaz-Cruz, C. L. Shapiro, and R. W. Brueggemeier Cyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer Cells J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2563 - 2570. [Abstract] [Full Text] [PDF]

				M. Heneweer, M. Muusse, M. Dingemans, P. C. de Jong, M. van den Berg, and J. T. Sanderson Co-culture of Primary Human Mammary Fibroblasts and MCF-7 Cells as an In Vitro Breast Cancer Model Toxicol. Sci., February 1, 2005; 83(2): 257 - 263. [Abstract] [Full Text] [PDF]

				K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2 Am. J. Pathol., February 1, 2005; 166(2): 575 - 584. [Abstract] [Full Text] [PDF]

				J. Zhou, T. Suzuki, A. Kovacic, R. Saito, Y. Miki, T. Ishida, T. Moriya, E. R. Simpson, H. Sasano, and C. D. Clyne Interactions between Prostaglandin E2, Liver Receptor Homologue-1, and Aromatase in Breast Cancer Cancer Res., January 15, 2005; 65(2): 657 - 663. [Abstract] [Full Text] [PDF]

				L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]

				S. Matsuzaki, M. Canis, C. Vaurs-Barriere, J.L. Pouly, O. Boespflug-Tanguy, F. Penault-Llorca, P. Dechelotte, B. Dastugue, K. Okamura, and G. Mage DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection Mol. Hum. Reprod., October 1, 2004; 10(10): 719 - 728. [Abstract] [Full Text] [PDF]

				S.-H. Chang, C. H. Liu, R. Conway, D. K. Han, K. Nithipatikom, O. C. Trifan, T. F. Lane, and T. Hla From the Cover: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression PNAS, January 13, 2004; 101(2): 591 - 596. [Abstract] [Full Text] [PDF]